Development of these therapeutics has arisen from an increased understanding of the diverse molecular characteristics of breast tumours such as expression of receptors for oestrogen, progesterone or amplification of human epidermal growth factor receptor 2 (HER2). Here, ERBB2 is linked to breast neoplasm.